Published in Br J Cancer on March 01, 1996
Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 35.74
The Fas death factor. Science (1995) 13.81
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature (1994) 11.22
Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature (1991) 5.80
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature (1994) 5.58
Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis. Proc Natl Acad Sci U S A (1983) 4.81
Programmed cell death: apoptosis and oncogenesis. Cell (1991) 4.78
Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med (1993) 4.53
Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell (1994) 4.26
Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med (1991) 4.15
Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res (1993) 4.11
Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature (1990) 3.80
Hybrid antibodies can target sites for attack by T cells. Nature (1985) 2.36
Induction of target cell DNA release by the cytotoxic T lymphocyte granule protease granzyme A. J Exp Med (1989) 1.91
Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A. Cell (1992) 1.82
Apoptosis: molecular mechanisms in programmed cell death. Eur J Cell Biol (1991) 1.74
Activation-driven T cell death. II. Quantitative differences alone distinguish stimuli triggering nontransformed T cell proliferation or death. J Immunol (1992) 1.62
Purified perforin induces target cell lysis but not DNA fragmentation. J Exp Med (1989) 1.47
A novel ligand in lymphocyte-mediated cytotoxicity: expression of the beta subunit of H+ transporting ATP synthase on the surface of tumor cell lines. J Exp Med (1994) 1.30
Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res (1985) 1.28
Debate: the mechanism of lymphocyte-mediated killing. Lymphocyte-triggered internal target disintegration. Immunol Today (1991) 1.04
Proteases and lymphocyte cytotoxic killing mechanisms. Curr Opin Immunol (1993) 1.03
Activation through CD3 molecule leads to clonal expansion of all human peripheral blood T lymphocytes: functional analysis of clonally expanded cells. J Immunol (1985) 1.00
Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer (1994) 0.95
Debate: the mechanism of lymphocyte-mediated killing. Perforin-induced pore formation. Immunol Today (1991) 0.89
Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother (1993) 0.88
The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol (1991) 0.83
Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules. Int J Cancer Suppl (1992) 0.81
Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes. Cancer Immunol Immunother (1991) 0.81
The role of apoptosis in antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother (1993) 0.77
Elastic properties of lipid bilayers: theory and possible experiments. Z Naturforsch C (1974) 19.89
Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet (1985) 10.67
Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol (1988) 4.05
Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol (1988) 3.76
Conjugation of fluorescein isothiocyanate to antibodies. II. A reproducible method. Immunology (1970) 3.09
Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med (1989) 2.94
Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues. J Gen Virol (1995) 2.66
Measurement of the curvature-elastic modulus of egg lecithin bilayers. Biochim Biophys Acta (1976) 2.59
Antibody reactions to virus-specific early antigens (EA) in patients with cytomegalovirus (CMV) infection. Clin Exp Immunol (1974) 2.57
Conjugation of fluorescein isothiocyanate to antibodies. I. Experiments on the conditions of conjugation. Immunology (1970) 2.56
Release of outer membrane fragments from normally growing Escherichia coli. Biochim Biophys Acta (1976) 2.51
Impact of dosage frequency on patient compliance. Diabetes Care (1997) 2.43
Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum (1990) 2.24
Demonstration of IgM cytomegalovirus-antibodies as an aid to early diagnosis in adults. Clin Exp Immunol (1970) 2.24
A region of the Herpesvirus saimiri genome required for oncogenicity. Science (1985) 2.22
Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation--a report of 130 consecutive patients. Transplantation (1989) 2.20
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med (2000) 2.19
Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis (1995) 2.16
Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med (1995) 2.13
Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet (1990) 2.12
Magnetic anisotropy of egg lecithin membranes. Biophys J (1978) 1.90
Construction of replication-competent Herpesvirus saimiri deletion mutants. J Virol (1984) 1.89
Red blood cell shapes as explained on the basis of curvature elasticity. Biophys J (1976) 1.85
Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health (1992) 1.81
Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int (1990) 1.77
An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun (1999) 1.75
Blocked lipid exchange in bilayers and its possible influence on the shape of vesicles. Z Naturforsch C (1974) 1.70
Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci (1983) 1.69
Conditional identification of phosphate-starvation-response mutants in Arabidopsis thaliana. Planta (2000) 1.68
The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection. J Gen Virol (1992) 1.67
Absence of jaagsiekte sheep retrovirus DNA and RNA in bronchioloalveolar and conventional human pulmonary adenocarcinoma by PCR and RT-PCR analysis. Hum Pathol (2001) 1.66
Schmallenberg virus antibodies in bovine and ovine fetuses. Vet Rec (2012) 1.65
Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury. Kidney Int (2008) 1.64
Detection of immunoglobulin M and G antibodies against cytomegalovirus early and late antigens by enzyme-linked immunosorbent assay. J Clin Microbiol (1984) 1.64
Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J Infect Dis (1993) 1.62
Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. J Hypertens (1997) 1.62
Clinical characterization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features. J Clin Oncol (1989) 1.59
Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis (1991) 1.59
Clinically silent rabies infection in (zoo) bats. Vet Rec (1998) 1.58
Magnetic anisotropy of lecithin membranes. A new anisotropy susceptometer. Biophys J (1984) 1.58
The immune response during the luteal phase of the ovarian cycle: a Th2-type response? Fertil Steril (2000) 1.57
Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol (1992) 1.55
Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors. Trop Med Int Health (2001) 1.51
Osmotic shrinkage of giant egg-lecithin vesicles. Biophys J (1981) 1.50
Antibodies against cytomegalovirus-induced early antigens (CMV-EA) in immunosuppressed renal-allograft recipients. Clin Exp Immunol (1977) 1.49
Peptides which bind to E-selectin and block neutrophil adhesion. J Biol Chem (1995) 1.48
A gene for dihydrofolate reductase in a herpesvirus. Science (1988) 1.47
Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol (1997) 1.46
Rapid detection of infectious cytomegalovirus in blood with the aid of monoclonal antibodies. J Med Virol (1987) 1.42
Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis (1982) 1.39
Cytomegalovirus antigenemia assay. J Clin Microbiol (1991) 1.39
Characterization of two classes of ribonucleoprotein complexes possibly involved in RNA editing from Leishmania tarentolae mitochondria. EMBO J (1994) 1.36
Tissue macrophages are infected by human cytomegalovirus in vivo. J Infect Dis (1996) 1.35
Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response. Clin Exp Immunol (1981) 1.34
Antibodies against membrane antigens of cytomegalovirus infected cells in sera of patients with a cytomegalovirus infection. Clin Exp Immunol (1972) 1.34
Specific MR imaging of human lymphocytes by monoclonal antibody-guided dextran-magnetite particles. Magn Reson Med (1992) 1.33
Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. J Biol Chem (1994) 1.33
Cytomegalovirus antigenemia: clinical correlations in transplant recipients and in persons with AIDS. J Clin Microbiol (1993) 1.33
Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions. Mol Cell Biol (2001) 1.32
Presence of human cytomegalovirus (HCMV) immediate early mRNA but not ppUL83 (lower matrix protein pp65) mRNA in polymorphonuclear and mononuclear leukocytes during active HCMV infection. J Gen Virol (1994) 1.30
Early serodiagnosis of acute human cytomegalovirus infection by enzyme-linked immunosorbent assay using recombinant antigens. J Clin Microbiol (1994) 1.29
Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab (1994) 1.28
Systemic involvement and immunologic findings in patients presenting with Raynaud's phenomenon. Am J Med (1980) 1.28
Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res (1985) 1.28
The origin and molecular characterization of adenoid basal carcinoma of the uterine cervix. Int J Gynecol Pathol (1997) 1.24
Induction of apoptosis through B-cell receptor cross-linking occurs via de novo generated C16-ceramide and involves mitochondria. J Biol Chem (2001) 1.24
Immune-complex glomerulopathy in patients treated with captopril. Lancet (1980) 1.23
B cell activity in systemic lupus erythematosus: depressed in vivo humoral immune response to a primary antigen (haemocyanin) and increased in vitro spontaneous immunoglobulin synthesis. Clin Exp Immunol (1983) 1.22
Acute cytomegalovirus infection and the host immune response. I. Development and maintenance of cytomegalovirus (CMV) induced in vitro lymphocyte reactivity and its relationship to the production of CMV antibodies. Clin Exp Immunol (1980) 1.22
Cardiovascular diseases and risk factors in a population-based study in The Netherlands: agreement between questionnaire information and medical records. Neth J Med (1999) 1.22
Monoclonal Antibodies to the Cell-Wall-Associated Proteinase of Lactococcus lactis subsp. cremoris Wg2. Appl Environ Microbiol (1988) 1.21
Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol (1998) 1.18
Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection. Clin Exp Immunol (1990) 1.16
Mapping of RNA transcribed from a region of the Herpesvirus saimiri genome required for oncogenicity. J Virol (1984) 1.14
Early detection of active cytomegalovirus (CMV) infection after heart and kidney transplantation by testing for immediate early antigenemia and influence of cellular immunity on the occurrence of CMV infection. J Clin Microbiol (1990) 1.14
T-DNA organization in homogeneous and heterogeneous octopine-type crown gall tissues of Nicotiana tabacum. Cell (1982) 1.14
NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med (1998) 1.14
Cytomegalovirus (CMV) antigenemia: rapid diagnosis and relationship with CMV-associated clinical syndromes in renal allograft recipients. Transplant Proc (1989) 1.13
The DNA-binding protein pUL57 of human cytomegalovirus is a major target antigen for the immunoglobulin M antibody response during acute infection. J Clin Microbiol (1995) 1.12
The human immune response to alpha-haemocyanin of Helix pomatia. Acta Med Scand (1973) 1.11
Direct visualisation and quantification of cellular cytotoxicity using two colour flourescence. J Immunol Methods (1992) 1.11
Scenario analysis of the future of medicines. BMJ (1994) 1.11
Selective MR imaging of labeled human peripheral blood mononuclear cells by liposome mediated incorporation of dextran-magnetite particles. Magn Reson Med (1993) 1.11
Neuroendocrine differentiation antigen on human lung carcinoma and Kulchitski cells. Cancer Res (1985) 1.11
Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. Am J Med (1991) 1.11
A standrard method for DNCB sensitization testing in patients with neoplasms. Cancer (1974) 1.11
Serum as a modulator of lipoplex-mediated gene transfection: dependence of amphiphile, cell type and complex stability. J Gene Med (2001) 1.10
Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg (1993) 1.10
Information on drug use in the elderly: a comparison of pharmacy, general-practitioner and patient data. Pharm World Sci (1995) 1.10
Class-specific antibody titres (ELISA) against the primary immunogen Helix pomatia haemocyanin (HPH) in man. Clin Exp Immunol (1978) 1.10
Influence of question structure on the recall of self-reported drug use. J Clin Epidemiol (2000) 1.10
Cytomegalovirus-directed lymphocyte reactivity in healthy adults tested by a CMV-induced lymphocyte transformation test. Clin Exp Immunol (1977) 1.10
Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics (1992) 1.10